HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist with the potential to treat a wide range of cancers in combination with other immunotherapiesHTL0039732, was found to be well-tolerated, confirmed target engagement and demonstrated encouraging early efficacy in two distinct tumor types when administered in combination use with atezolizumabPhase 1 trial met the key objectives and identified a dose for a Phase 2 expansion trial, which is now underwayCancer Research UK’s Centre for Dr ...